Objective Glenohumeral (GH) osteoarthritis (OA) is the third most common large joint disease, after hip and knee OA. This ...

The county’s internal auditor reported that in a sampling of contracts and expenditures paid for with American Rescue Plan ...

When people say "data is the new oil," they're usually referring to its value. But in reality, oil requires careful handling, management, ...

SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.

The initial assessments, which also cover quantum technologies, are due July 15, with a full assessment coming by March 2026.

Getty Images The risk-free rate of return is one of the most basic components of modern finance. The risk-free asset only applies in theory, but its actual safety rarely comes into question until ...

NASA’s troubled Mars Sample Return program is stuck at a crossroads ... Tuesday’s briefing revealed the results of that independent assessment, giving two potential options for a speedier ...